EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Assessing the utility of the PC‐PTSD‐5 as a screening tool among a cancer survivor sample

Sophia K Smith iD, Cole Manschot, Eric Kuhn, Eric Laber, Tamara J Somers iD, Karen L Syrjala, Allison J Applebaum

Cancer · 2024-12 · 130 (23) · 4118-4126

DOI: 10.1002/cncr.35504 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer, online erschienen am 14.08.2024. Verfasst von Sophia K Smith und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, Duke University, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Cancer Survivors, Stress Disorders, Post-Traumatic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hematopoietic stem cell transplantation (HCT) is an intensive and invasive procedure used in cancer treatment that can lead to posttraumatic stress disorder (PTSD) symptoms. These symptoms are frequently overlooked in oncology and general health care settings. The suitability and utility of the Primary Care PTSD Screen for DSM‐5 (PC‐PTSD‐5) within the cancer population remains uncertain. This study aims to evaluate its performance as a brief (five‐item) case‐finding screening alternative to the longer (20‐item) PTSD Checklist for DSM‐5 (PCL‐5) in survivors who received an HCT 1 to 5 years ago.

Methods

A total of 817 cancer survivors completed the PC‐PTSD‐5 and PCL‐5 during recruitment for a randomized clinical trial. Optimal cut scores for identifying probable PTSD and item performance were determined using indices correcting for chance and item response theory analyses.

Results

Of the HCT sample, 25.7% screened as positive for probable DSM‐5 PTSD using the PCL‐5. The PC‐PTSD‐5 exhibited strong internal consistency and significant associations with PCL‐5 scores (total, r = .82; items, r s = .56–.61). A cutoff score of 2 provided optimal sensitivity for screening (κ[Se] = .94), whereas a cut score of 4 demonstrated the highest efficiency for detecting a probable DSM‐5 PTSD diagnosis on the PCL‐5 (κ[Eff] = .60). Item response theory analyses indicated that item 2 (avoidance) of the PC‐PTSD‐5 yielded the most informative data, with other items potentially lacking incremental utility.

Conclusion

Although not an instrument validation study, these findings offer efficient evidence for using the PC‐PTSD‐5 as a succinct screening tool among cancer survivors in a clinical context. Trials Registration ClinicalTrials.gov , NCT04058795, registered 8/16/2019

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer SurvivorsStress Disorders, Post-TraumaticHumansFemaleMaleMiddle AgedAdultAgedHematopoietic Stem Cell TransplantationMass ScreeningNeoplasmsChecklist

Stichwörter der Autor:innen

HCTPCL‐5PC‐PTSD‐5PTSDcancer survivorposttraumatic stressscreening

Autor:innen und Institutionen

  • School of Nursing, Duke University, Durham, North Carolina, USA.
  • Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
  • North Carolina State University, Raleigh, North Carolina, USA.
  • Dissemination and Training Division, National Center for PTSD, Palo Alto, California, USA.
  • Department of Psychiatry and Behavioral Sciences, School of Medicine, Stanford University, Stanford, California, USA.
  • Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.

ORCID-Profile: Sophia K Smith, Tamara J Somers

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Smith, S. K., Manschot, C., Kuhn, E., Laber, E., Somers, T. J., Syrjala, K. L., & Applebaum, A. J. (2024). Assessing the utility of the PC‐PTSD‐5 as a screening tool among a cancer survivor sample. Cancer, 130(23), 4118-4126. https://doi.org/10.1002/cncr.35504

Vancouver

Smith SK, Manschot C, Kuhn E, Laber E, Somers TJ, Syrjala KL, et al. Assessing the utility of the PC‐PTSD‐5 as a screening tool among a cancer survivor sample. Cancer. 2024;130(23):4118-4126. doi:10.1002/cncr.35504

BibTeX
@article{Smith2024,
  author = {Smith, Sophia K and Manschot, Cole and Kuhn, Eric and Laber, Eric and Somers, Tamara J and Syrjala, Karen L and Applebaum, Allison J},
  title = {Assessing the utility of the PC‐PTSD‐5 as a screening tool among a cancer survivor sample},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {23},
  pages = {4118--4126},
  doi = {10.1002/cncr.35504}
}
Kostenlos starten →